Risk factors for immune-related adverse events caused by immune checkpoint inhibitors in patients with lung cancer: a single-institution retrospective study

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100045121

Enrollment

Unknown

Registered

2021-04-07

Start date

2021-07-01

Completion date

Unknown

Last updated

2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

case series:immune checkpoint inhibitors

Eligibility

Sex/Gender

All

Age

1 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients with confirmed lung cancer. 2. Patients who received ICI treatment for the first time from January 2016 to December 2020.

Exclusion criteria

Exclusion criteria: The patient's case data is incomplete.

Design outcomes

Primary

Measure	Time frame
immune-related adverse events;	—

Countries

China

Contacts

Public ContactMu deguang

Zhejiang Provincial People's Hospital

mudeguang@126.com+86 15858279340

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026